Key Takeaways RARE rises 15.5% after finishing its rolling BLA submission to the FDA for DTX401 in GSDIa.DTX401 aims to treat the underlying cause of GSDIa, a rare disorder with no approved drug therapies.RARE's BLA is backed by phase III data showing reduced cornstarch use and improved glucose control.Shares of Ultragenyx Pharmaceutical (RARE) were up 15.5% yesterday following the completion of the rolling submission of a biologics license application (“BLA”) to the FDA seeking approval for its AAV gene th ...

Ultragenyx (RARE) shares ended the last trading session 15.5% higher at $22.78. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 40.9% loss over the past four weeks.The stock rallied, driven by optimism over the company’s completion of the rolling submission of a biologics license application (“BLA”) to the FDA seeking approval for its AAV gene therapy, DTX401 (pariglasgene brecaparvovec), for the treatment of glyco ...